Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3956MR)

This product GTTS-WQ3956MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3956MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4049MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ12241MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ13345MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ14261MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ3003MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Angiocept
GTTS-WQ11875MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ4773MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ7769MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW